Compare NSRX & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSRX | KYNB |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | Israel | United States |
| Employees | 7 | 34 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 27.6M |
| IPO Year | N/A | N/A |
| Metric | NSRX | KYNB |
|---|---|---|
| Price | $3.20 | $7.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | ★ 52.6K | 6.5K |
| Earning Date | 03-25-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $6.32 |
| 52 Week High | $9.99 | $9.58 |
| Indicator | NSRX | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 50.31 |
| Support Level | $2.04 | $6.73 |
| Resistance Level | $3.48 | $7.42 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 63.64 | 53.93 |
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.